On August 20, REMEGEN rose 5.2% in regular trading, trading at HK$83.65/share, with turnover of HK$127 million. The stock was lifted by a combination of an imminent mid-term earnings release and broad-based strength across the biotech sector.

The company is scheduled to hold a board meeting on August 24 to review and approve its interim results for the six months ended June 30. According to a prior earnings preview, REMEGEN expects H1 revenue of approximately RMB 58.5 billion, up about 433% year-over-year, and net profit of approximately RMB 47 billion, achieving a turnaround from losses. The dramatic improvement was primarily driven by a major licensing deal with AbbVie for RC148, alongside continued domestic sales growth of core products Telitacicept and Disitamab Vedotin.

Additionally, the company announced on August 18 an additional US$30 million purchase of OCBC structured deposits, bringing total financial product holdings to US$100 million within six months, signaling robust cash reserves. The biotech sector rallied broadly on the same day, with Everest Medicines up 48.66%, CanSino Bio up 46.62%, and Akeso up 7.95%, creating strong sector linkage effects.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)